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BACKGROUND
Patients with advanced urothelial carcinoma that progresses after platinum-based chemo-
therapy have a poor prognosis and limited treatment options.
METHODS
In this open-label, international, phase 3 trial, we randomly assigned 542 patients with 
advanced urothelial cancer that recurred or progressed after platinum-based chemother-
apy to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype 
antibody against programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the 
investigator’s choice of chemotherapy with paclitaxel, docetaxel, or vinflunine. The copri-
mary end points were overall survival and progression-free survival, which were assessed 
among all patients and among patients who had a tumor PD-1 ligand (PD-L1) combined 
positive score (the percentage of PD-L1–expressing tumor and infiltrating immune cells 
relative to the total number of tumor cells) of 10% or more.
RESULTS
The median overall survival in the total population was 10.3 months (95% confidence 
interval [CI], 8.0 to 11.8) in the pembrolizumab group, as compared with 7.4 months 
(95% CI, 6.1 to 8.3) in the chemotherapy group (hazard ratio for death, 0.73; 95% CI, 0.59 
to 0.91; P = 0.002). The median overall survival among patients who had a tumor PD-L1 
combined positive score of 10% or more was 8.0 months (95% CI, 5.0 to 12.3) in the 
pembrolizumab group, as compared with 5.2 months (95% CI, 4.0 to 7.4) in the chemo-
therapy group (hazard ratio, 0.57; 95% CI, 0.37 to 0.88; P = 0.005). There was no signifi-
cant between-group difference in the duration of progression-free survival in the total 
population (hazard ratio for death or disease progression, 0.98; 95% CI, 0.81 to 1.19; 
P = 0.42) or among patients who had a tumor PD-L1 combined positive score of 10% or 
more (hazard ratio, 0.89; 95% CI, 0.61 to 1.28; P = 0.24). Fewer treatment-related adverse 
events of any grade were reported in the pembrolizumab group than in the chemothera-
py group (60.9% vs. 90.2%); there were also fewer events of grade 3, 4, or 5 severity re-
ported in the pembrolizumab group than in the chemotherapy group (15.0% vs. 49.4%).
CONCLUSIONS
Pembrolizumab was associated with significantly longer overall survival (by approxi-
mately 3 months) and with a lower rate of treatment-related adverse events than chemo-
therapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. 
(Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436.)
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Urothelial cancer is highly lethal in the metastatic state.1 Platinum-based combination chemotherapy remains the 
standard first-line treatment for metastatic dis-
ease. Carboplatin-based combinations are associ-
ated with a median overall survival of 9 months,2 
and cisplatin-based combinations with a median 
overall survival of 12 to 15 months.3 However, 
after platinum-based chemotherapy, there is no 
internationally accepted standard of care. Single-
agent paclitaxel and docetaxel are commonly 
used worldwide,4,5 and in Europe, vinflunine has 
been approved on the basis of an overall survival 
advantage of 2 months over best supportive 
care.6,7 Because the median overall survival with 
second-line therapy is only 6 to 7 months, effec-
tive options are needed in patients with previ-
ously treated advanced urothelial carcinoma.
Monoclonal antibodies against programmed 
death 1 (PD-1) and its ligands (PD-L1 and PD-L2) 
have shown robust antitumor activity and a man-
ageable safety profile in many advanced malig-
nant conditions,8 including urothelial cancer.9-14 
Pembrolizumab, a highly selective, humanized 
monoclonal IgG4κ isotype antibody against PD-1, 
can disrupt the engagement of PD-1 with its 
ligands and impede inhibitory signals in T cells. 
Pembrolizumab showed antitumor activity in pa-
tients with advanced urothelial carcinoma in the 
phase 1b KEYNOTE-012 study9 and the phase 2 
KEYNOTE-052 study.12 In the international, ran-
domized, open-label, phase 3 KEYNOTE-045 trial, 
we compared pembrolizumab with investigator’s 
choice of chemotherapy with paclitaxel, docetaxel, 
or vinflunine as second-line therapy in patients 
with advanced urothelial carcinoma that pro-
gressed during or after the receipt of platinum-
based chemotherapy.
Me thods
Patients
Patients who were 18 years of age or older were 
eligible for enrollment if they had histologically 
or cytologically confirmed urothelial carcinoma of 
the renal pelvis, ureter, bladder, or urethra that 
showed predominantly transitional-cell features 
on histologic testing, had progression after 
platinum-based chemotherapy for advanced dis-
ease or recurrence within 12 months after the 
receipt of platinum-based adjuvant or neoadjuvant 
therapy for localized muscle-invasive disease, had 
received two or fewer lines of systemic chemo-
therapy for advanced disease previously, had at 
least one measurable lesion according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1,15 and had an Eastern Co-
operative Oncology Group (ECOG) performance-
status score of 0, 1, or 2 (on a 5-point scale, with 
0 indicating no symptoms and higher numbers 
indicating greater disability). Patients who had 
an ECOG performance-status score of 2 (indicat-
ing that the patient is ambulatory and capable of 
all self-care but is unable to carry out any work 
activities and is out of bed more than 50% of 
waking hours) and had one or more of the estab-
lished poor prognostic factors for second-line 
therapy (i.e., hemoglobin concentration of <10 g 
per deciliter, presence of liver metastases, and 
receipt of the last dose of most recent chemo-
therapy <3 months before enrollment)16,17 were 
excluded from enrollment. Patients were ineli-
gible if they had received anti–PD-1, anti–PD-L1, 
or anti–CTLA-4 therapy previously. Full eligibil-
ity criteria are listed in the trial protocol, avail-
able with the full text of this article at NEJM.org.
Trial Design and Treatment
Patients were randomly assigned in a 1:1 ratio to 
receive pembrolizumab (at a dose of 200 mg) or 
investigator’s choice of paclitaxel (at a dose of 
175 mg per square meter of body-surface area), 
docetaxel (at a dose of 75 mg per square meter), 
or vinflunine (at a dose of 320 mg per square me-
ter), all administered intravenously every 3 weeks. 
Randomization was stratified according to ECOG 
performance-status score (0 or 1 vs. 2), presence 
of liver metastases (yes vs. no), hemoglobin con-
centration (<10 g per deciliter vs. ≥10 g per deci-
liter), and time since the last dose of chemo-
therapy (<3 months vs. ≥3 months). Treatment 
assignment was not blinded. Treatment was 
continued until RECIST-defined disease progres-
sion,15 development of an unacceptable level of 
toxic effects, withdrawal of consent, decision by 
the investigator to discontinue treatment, or the 
completion of 2 years of pembrolizumab therapy.
Patients with disease progression, according 
to the investigator’s assessment of radiographic 
results, and a clinically stable status could con-
tinue to receive the therapy at the discretion of 
the investigator. Patients in the pembrolizumab 
group who had a complete response could dis-
continue treatment if they had received pembro-
lizumab for at least 24 weeks and for at least two 
doses beyond the time of initial complete re-
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sponse. There was no planned crossover on dis-
ease progression. Full information about guid-
ance regarding the treatment decisions is provided 
in the protocol.
Assessments
PD-L1 expression was assessed in formalin-fixed 
tumor samples at a central laboratory with the use 
of the commercially available PD-L1 IHC 22C3 
pharmDx assay (Dako North America). The kits 
were purchased at full cost. Archival tumor 
samples and newly obtained core or excisional 
biopsy samples from nonirradiated sites were 
permitted. There were no restrictions on the age 
of the archival samples or on the number of in-
tervening therapies received after the sample was 
obtained. All samples, regardless of whether 
they were archival or newly obtained, were ana-
lyzed by the central laboratory during the screen-
ing process, and only the patients whose sam-
ples could be evaluated for PD-L1 expression were 
permitted to enroll in the study. PD-L1 expression 
was categorized as the PD-L1 combined positive 
score, defined as the percentage of PD-L1–express-
ing tumor and infiltrating immune cells relative 
to the total number of tumor cells.12
Tumor imaging was scheduled for week 9, 
followed by every 6 weeks during the first year 
and every 12 weeks thereafter. Response to 
treatment was assessed according to RECIST15 by 
means of blinded, independent, central radiologic 
review. During follow-up for survival, patients 
were contacted every 12 weeks for survival assess-
ment. The full assessment schedule is provided 
in the trial protocol. All the adverse events and 
abnormalities were graded according to the Na-
tional Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0.
End Points
At the second interim analysis, the coprimary 
end points were overall survival and progression-
free survival, which were assessed in the total 
population and in the population of patients 
who had a tumor PD-L1 combined positive score 
of 10% or more. Overall survival was defined as 
the time from randomization to death from any 
cause. Progression-free survival was defined as 
the time from randomization to disease pro-
gression or death from any cause.
Secondary efficacy end points, which were as-
sessed in the total population and in the popula-
tion of patients who had a tumor PD-L1 com-
bined positive score of 10% or more, included 
the objective response rate, defined as the per-
centage of patients who had a confirmed com-
plete or partial response, and the duration of 
confirmed response, defined as the time from the 
first documented complete or partial response 
to disease progression or death. Safety in the 
total population was also a secondary end point. 
The full list of end points is provided in the 
protocol.
Efficacy was assessed in the intention-to-treat 
population, which included all the patients who 
were assigned to a treatment group. Safety was 
assessed in the as-treated population, which 
included all the patients who received at least 
one dose of study treatment.
Trial Oversight
The trial was designed by academic advisors and 
employees of the sponsor (Merck). Data were col-
lected by investigators and their site personnel 
and analyzed by statisticians who were employees 
of the sponsor. Results were interpreted by the 
academic authors, by authors who were employ-
ees of the sponsor, and by other employees of 
the sponsor who did not fulfill all the authorship 
criteria as outlined by the International Commit-
tee of Medical Journal Editors. An external data 
and safety monitoring committee oversaw the 
trial and assessed efficacy and safety at the time 
of prespecified interim analyses that were per-
formed by statisticians from QuintilesIMS, with 
funding by the sponsor.
The trial protocol and all the amendments 
were approved by the appropriate ethics body at 
each center. The trial was conducted in accor-
dance with the protocol and its amendments, 
with Good Clinical Practice guidelines, and with 
the provisions of the Declaration of Helsinki. All 
the patients provided written informed consent 
before enrollment.
All the authors attest that the trial was con-
ducted in accordance with the protocol and all 
the amendments, attest that they had access to 
the data used for the writing of the manuscript, 
and vouch for the accuracy and completeness of 
the data and analyses. The first draft of the 
manuscript was written by the first and last au-
thors, with input from authors who were employ-
ees of the sponsor. Assistance with manuscript 
preparation was provided by a medical writer 
employed by the sponsor. All the authors partici-
pated in reviewing and editing the manuscript 
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and made the decision to submit the manuscript 
for publication.
Statistical Analysis
Overall survival, progression-free survival, and 
duration of response were estimated with the use 
of the Kaplan–Meier method. In the analysis of 
overall survival, patients who were alive or lost to 
follow-up had their data censored at the time of 
last contact. In the analysis of progression-free 
survival, patients who were alive and without dis-
ease progression or who were lost to follow-up 
had their data censored at the time of last tumor 
assessment. Between-group differences in overall 
survival and progression-free survival were calcu-
lated with the use of a stratified log-rank test. 
Hazard ratios and associated 95% confidence in-
tervals were calculated with the use of a stratified 
Cox proportional-hazards model and Efron’s meth-
od of handling ties. Differences in the response 
rate were calculated with the stratified Miettinen 
and Nurminen method. The same stratification 
factors that were used for randomization were 
applied to all stratified efficacy analyses.
The overall family-wise type I error rate was 
strictly controlled at a one-sided alpha level of 
2.5%. We calculated that enrollment of 470 pa-
tients would provide the study with 88% power 
to show a hazard ratio for death of 0.781 or bet-
ter in the analysis of overall survival in the pem-
brolizumab group versus the chemotherapy group 
in the total population and 86% power to show 
a hazard ratio of 0.625 or better in the pembro-
lizumab group versus the chemotherapy group 
among patients who had a tumor PD-L1 combined 
positive score of 10% or more.
The protocol specified two interim analyses 
before the final analysis. After reviewing the 
first interim analysis, the data and safety moni-
toring committee recommended continuing the 
study as planned. The second interim analysis 
was based on a cutoff date of September 7, 2016, 
and was performed after 334 deaths had oc-
curred in the total population and 104 deaths 
had occurred in the population of patients who 
had a tumor PD-L1 combined positive score of 
10% or more. The data and safety monitoring 
committee reviewed the results of the second 
interim analysis on October 18, 2016, and recom-
mended early termination of the trial because 
pembrolizumab met the superiority thresholds 
for overall survival in the coprimary populations 
(Table S1 in the Supplementary Appendix, avail-
able at NEJM.org). All the data reported herein 
are those from the second interim analysis. The 
full statistical analysis plan is available in the 
protocol.
R esult s
Patients and Treatment
A total of 748 patients were screened for enroll-
ment at 120 sites in 29 countries. Between No-
vember 5, 2014, and November 13, 2015, a total 
of 542 patients were randomly assigned to pem-
brolizumab (270 patients) or investigator’s choice 
of chemotherapy (272). Of these, 266 patients in 
the pembrolizumab group and 255 in the chemo-
therapy group received treatment (Fig. S1 in the 
Supplementary Appendix). In the chemotherapy 
group, 84 patients received docetaxel, 84 received 
paclitaxel, and 87 received vinflunine. The demo-
graphic and disease characteristics of the patients 
at baseline were generally balanced between the 
two treatment groups (Table 1, and Table S2 in 
the Supplementary Appendix). A total of 164 pa-
tients (30.3%), including 74 patients in the pem-
brolizumab group and 90 in the chemotherapy 
group, had a tumor PD-L1 combined positive 
score of 10% or more (Table S3 in the Supple-
mentary Appendix).
The median duration of follow-up, defined as 
the time from randomization to September 7, 
2016, was 14.1 months (range, 9.9 to 22.1). In 
the as-treated population, the median duration of 
study treatment was 3.5 months (range, <0.1 to 
20.0) in the pembrolizumab group and 1.5 months 
(range, <0.1 to 14.2) in the chemotherapy group. 
A total of 49 patients (18.4%) in the pembrolizu-
mab group and 3 (1.2%) in the chemotherapy 
group were still receiving study treatment at the 
time of data cutoff (Fig. S1 in the Supplementary 
Appendix). In the intention-to-treat population, 
68 patients (25.2%) in the pembrolizumab group 
and 91 (33.5%) in the chemotherapy group re-
ceived subsequent therapy, including 2 patients 
(0.7%) and 35 patients (12.9%), respectively, who 
received subsequent immunotherapy.
Overall Survival
As of September 7, 2016, a total of 334 deaths 
had occurred in the intention-to-treat population. 
Overall survival was significantly longer in the 
pembrolizumab group than in the chemotherapy 
group (hazard ratio for death, 0.73; 95% con-
fidence interval [CI], 0.59 to 0.91; P = 0.002) 
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(Fig. 1A). The median overall survival was 10.3 
months (95% CI, 8.0 to 11.8) in the pembroli-
zumab group, as compared with 7.4 months 
(95% CI, 6.1 to 8.3) in the chemotherapy group. 
The estimated overall survival rate at 12 months 
was 43.9% (95% CI, 37.8 to 49.9) in the pembro-
lizumab group, as compared with 30.7% (95% 
CI, 25.0 to 36.7) in the chemotherapy group.
Pembrolizumab was also associated with sig-
nificantly longer overall survival than chemo-
therapy in the coprimary population of patients 
who had a tumor PD-L1 combined positive score 
of 10% or more (hazard ratio for death, 0.57; 
95% CI, 0.37 to 0.88; P = 0.005). The median 
overall survival was 8.0 months (95% CI, 5.0 to 
12.3) in the pembrolizumab group, as compared 
with 5.2 months (95% CI, 4.0 to 7.4) in the che-
motherapy group (Fig. S2A in the Supplementary 
Appendix). Pembrolizumab was associated with 
a benefit over chemotherapy in all the subgroups 
Characteristic
Pembrolizumab Group 
(N = 270)
Chemotherapy Group 
(N = 272)
Age — yr
Median 67 65
Range 29–88 26–84
Male sex — no. (%) 200 (74.1) 202 (74.3)
ECOG performance-status score — no. (%)†
0 119 (44.1) 106 (39.0)
1 143 (53.0) 158 (58.1)
2 2 (0.7) 4 (1.5)
Missing data 6 (2.2) 4 (1.5)
Current or former smoker — no./total no. (%) 165/269 (61.3) 186/269 (69.1)
Pure transitional-cell features in histologic testing — no./total no. (%) 186/270 (68.9) 197/270 (73.0)
Tumor PD-L1 combined positive score ≥10% — no./total no. (%)‡ 74/260 (28.5) 90/266 (33.8)
Site of primary tumor in bladder or urethra — no./total no. (%) 232/270 (85.9) 234/271 (86.3)
Visceral disease — no./total no. (%) 240/269 (89.2) 233/271 (86.0)
Liver metastases — no./total no. (%) 91/270 (33.7) 95/271 (35.1)
Hemoglobin concentration <10 g/dl — no./total no. (%) 43/262 (16.4) 44/267 (16.5)
No. of risk factors — no. (%)§
0 54 (20.0) 44 (16.2)
1 96 (35.6) 97 (35.7)
2 66 (24.4) 80 (29.4)
3 or 4 45 (16.7) 45 (16.5)
Missing data 9 (3.3) 6 (2.2)
Completion or discontinuation of most recent therapy <3 mo previously  
— no./total no. (%)
103/269 (38.3) 104/271 (38.4)
*  The intention-to-treat population included all the patients who underwent randomization. There were no significant differences between the 
two treatment groups. For the characteristics of current or former smoker, pure transitional-cell features on histologic testing, a tumor PD-L1 
combined positive score of 10% or more, site of primary tumor in bladder or urethra, visceral disease, liver metastases, hemoglobin con-
centration, and timing of completion or discontinuation of most recent therapy, percentages are calculated on the basis of the number of 
patients with available data. The full details regarding the demographic and disease characteristics at baseline are provided in Table S2 in 
the Supplementary Appendix.
†  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher 
scores indicating greater disability.
‡  The programmed death ligand 1 (PD-L1) combined positive score was defined as the percentage of tumor and infiltrating immune cells 
with PD-L1 expression out of the total number of tumor cells.
§  Risk factors include the Bellmunt risk factors of an ECOG performance-status score above 0, a hemoglobin concentration of less than 10 g  
per deciliter, and the presence of liver metastases,16 plus a time since the completion or discontinuation of previous therapy of less than  
3 months.17
Table 1. Demographic and Disease Characteristics at Baseline in the Intention-to-Treat Population.*
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examined, including among patients with liver 
metastases and those who had a tumor PD-L1 
combined positive score of less than 1% (Fig. 2). 
In an analysis that considered the chemotherapy 
regimens separately, the benefit of pembrolizu-
mab over chemotherapy was similar for each 
chemotherapy regimen (Fig. 2).
Progression-free Survival
A total of 437 events of disease progression or 
death occurred in the intention-to-treat popula-
tion, with no significant difference in the duration 
of progression-free survival between the pembro-
lizumab group and the chemotherapy group 
Figure 2 (facing page). Analysis of Overall Survival  
in Key Subgroups.
Eastern Cooperative Oncology Group (ECOG) perfor-
mance-status scores range from 0 to 5, with 0 indicat-
ing no symptoms and higher scores indicating greater 
disability; a score of 2 indicates that the patient is am-
bulatory and capable of all self-care but is unable to 
carry out any work activities and is out of bed more 
than 50% of waking hours. The programmed death li-
gand 1 (PD-L1) combined positive score was defined 
as the percentage of tumor and infiltrating immune 
cells with PD-L1 expression out of the total number of 
tumor cells. The upper tract was defined as the renal 
pelvis or ureter, and the lower tract as the bladder or 
urethra. Risk factors include the Bellmunt risk factors 
of an ECOG performance-status score above 0, a hemo-
globin concentration of less than 10 g per deciliter, and 
the presence of liver metastases,16 plus a time since the 
completion or discontinuation of previous therapy of 
less than 3 months.17 The number of patients in each 
of the subgroups of investigator’s choice of chemother-
apy represents the number of patients who received at 
least one dose of that treatment (84 patients received 
docetaxel, 84 paclitaxel, and 87 vinflunine) plus the 
number of patients who received at least one dose of 
pembrolizumab (266). For all other subgroups, the in-
tention-to-treat population was used. Data were miss-
ing as follows: ECOG performance-status score (10 pa-
tients), smoking status (4), histologic type (2), tumor 
PD-L1 combined positive score 1% cutoff (14), tumor 
PD-L1 combined positive score 10% cutoff (16), loca-
tion of primary tumor (1), location of metastases (2), 
liver metastases (1), hemoglobin concentration (13), 
number of risk factors (15), context of most recent 
therapy received (2), time since most recent chemo-
therapy (2), and type of previous platinum therapy (2). 
Data for 2 patients with other histologic type and for  
2 patients with other previous platinum therapy are 
also not shown. The dashed line indicates the rate of 
overall survival in the entire trial population.Figure 1. Overall Survival and Progression-free Survival in the Intention- 
to-Treat Population.
Shown are Kaplan–Meier estimates of overall survival and progression-free 
survival according to treatment group. Tick marks represent patients who 
had data censored at the last time that they were known to be alive (Panel A) 
or who were known to be alive and without disease progression as assessed 
per Response Evaluation Criteria in Solid Tumors, version 1.1, by blinded, 
independent, central radiologic review (Panel B). The intention-to-treat 
population included all the patients who underwent randomization. The 
one-sided superiority thresholds for pembrolizumab were a P value of 0.0123 
in the analysis of overall survival and a P value of 0.0151 in the analysis  
of progression-free survival. The median overall survival was 10.3 months 
(95% CI, 8.0 to 11.8) in the pembrolizumab group, as compared with 7.4 
months (95% CI, 6.1 to 8.3) in the chemotherapy group (44.8 weeks [95% 
CI, 34.8 to 51.3] vs. 32.2 weeks [95% CI, 26.5 to 36.1]). The median progres-
sion-free survival was 2.1 months (95% CI, 2.0 to 2.2) in the pembrolizumab 
group and 3.3 months (95% CI, 2.3 to 3.5) in the chemotherapy group  
(9.1 weeks [95% CI, 8.7 to 9.6] and 14.3 weeks [95% CI, 10.0 to 15.2], 
 respectively).
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1.0 5.0
Chemotherapy BetterPembrolizumab Better
Overall
Age
<65 yr
≥65 yr
Sex
Male
Female
ECOG performance-status score
0 or 1
2
Smoking status
Current
Former
Never
Histologic type
Transitional cell
Mixed
Tumor PD-L1 combined positive score, 1% cutoff
<1%
≥1%
Tumor PD-L1 combined positive score, 10% cutoff
<10%
≥10%
Location of primary tumor
Upper tract
Lower tract
Location of metastases
Lymph node only
Visceral disease
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(hazard ratio for death or disease progression, 
0.98; 95% CI, 0.81 to 1.19; P = 0.42) (Fig. 1B). The 
median progression-free survival was 2.1 months 
(95% CI, 2.0 to 2.2) in the pembrolizumab group 
and 3.3 months (95% CI, 2.3 to 3.5) in the chemo-
therapy group. The estimated progression-free 
survival rate at 12 months was 16.8% (95% CI, 
12.3 to 22.0) in the pembrolizumab group and 
6.2% (95% CI, 3.3 to 10.2) in the chemotherapy 
group. There was also no significant between-
group difference in the duration of progression-
free survival among patients who had a tumor 
PD-L1 combined positive score of 10% or more 
(hazard ratio, 0.89; 95% CI, 0.61 to 1.28; P = 0.24) 
(Fig. S2B in the Supplementary Appendix).
Objective Response
In the total population, the objective response 
rate was significantly higher in the pembrolizu-
mab group (21.1%; 95% CI, 16.4 to 26.5) than in 
the chemotherapy group (11.4%; 95% CI, 7.9 to 
15.8) (P = 0.001). The median time to response 
was 2.1 months in each group. The median dura-
tion of response was not reached in the pembro-
lizumab group (range, 1.6+ to 15.6+ months) 
and was 4.3 months (range, 1.4+ to 15.4+) in the 
chemotherapy group (Fig. 3). (Plus signs indicate 
an ongoing response at data cutoff.)
At the time of data cutoff, 41 of 57 patients 
(72%) with a response in the pembrolizumab 
group and 11 of 31 (35%) with a response in the 
chemotherapy group continued to have a response. 
Treatment was ongoing in 36 of 57 patients with 
a response (63%) in the pembrolizumab group and 
in 2 of 31 (6%) with a response in the chemo-
therapy group (Fig. 3). The estimated percentage 
of patients with a duration of response of at least 
12 months was 68% in the pembrolizumab group 
versus 35% in the chemotherapy group. Results 
were similar in the population of patients who 
had a tumor PD-L1 combined positive score of 
10% or more. Details are provided in Table S4 
and Figure S3 in the Supplementary Appendix.
Adverse Events
Adverse events that were considered by the in-
vestigators to be related to treatment occurred in 
60.9% of the patients treated with pembrolizu-
mab, as compared with 90.2% of those who re-
ceived chemotherapy (Table 2). Treatment-related 
events of grade 3, 4, or 5 severity were less fre-
quent in the pembrolizumab group than in the 
chemotherapy group (15.0% vs. 49.4% of patients), 
as was treatment-related discontinuation of ther-
apy (5.6% vs. 11.0%). One pembrolizumab-treated 
patient died from treatment-related pneumonitis. 
Three other deaths in the pembrolizumab group 
were attributed by the investigators to study treat-
ment, including one death related to urinary 
tract obstruction, one death related to malignant 
neoplasm progression, and one death of unspeci-
fied cause. In the chemotherapy group, treatment-
related deaths were related to sepsis (in two 
Figure 3. Time to Response and Duration of Response in Patients with a 
Confirmed Objective Response.
Response and disease progression were assessed according to the Response 
Evaluation Criteria in Solid Tumors, version 1.1, by blinded, independent, 
central radiologic review. Bars indicate the duration of response at the time 
of data cutoff.
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Event
Pembrolizumab Group 
(N = 266)
Chemotherapy Group 
(N = 255)
Any Grade Grade 3, 4, or 5 Any Grade Grade 3, 4, or 5
number of patients (percent)
Treatment-related event†
Any event 162 (60.9) 40 (15.0) 230 (90.2) 126 (49.4)
Event leading to discontinuation of 
treatment
15 (5.6) 12 (4.5) 28 (11.0) 16 (6.3)
Event leading to death 4 (1.5) 4 (1.5) 4 (1.6) 4 (1.6)
Event occurring in ≥10% of patients 
in either group‡
Pruritus 52 (19.5) 0 7 (2.7) 1 (0.4)
Fatigue 37 (13.9) 3 (1.1) 71 (27.8) 11 (4.3)
Nausea 29 (10.9) 1 (0.4) 62 (24.3) 4 (1.6)
Diarrhea 24 (9.0) 3 (1.1) 33 (12.9) 2 (0.8)
Decreased appetite 23 (8.6) 0 41 (16.1) 3 (1.2)
Asthenia 15 (5.6) 1 (0.4) 36 (14.1) 7 (2.7)
Anemia 9 (3.4) 2 (0.8) 63 (24.7) 20 (7.8)
Constipation 6 (2.3) 0 52 (20.4) 8 (3.1)
Peripheral sensory neuropathy 2 (0.8) 0 28 (11.0) 5 (2.0)
Neutrophil count decreased 1 (0.4) 1 (0.4) 36 (14.1) 31 (12.2)
Peripheral neuropathy 1 (0.4) 0 27 (10.6) 2 (0.8)
Neutropenia 0 0 39 (15.3) 34 (13.3)
Alopecia 0 0 96 (37.6) 2 (0.8)
Event of interest§
Any event 45 (16.9) 12 (4.5) 19 (7.5) 4 (1.6)
Hypothyroidism 17 (6.4) 0 3 (1.2) 0
Hyperthyroidism 10 (3.8) 0 1 (0.4) 0
Pneumonitis 11 (4.1) 6 (2.3) 1 (0.4) 0
Colitis 6 (2.3) 3 (1.1) 1 (0.4) 0
Infusion reaction 2 (0.8) 0 10 (3.9) 0
Nephritis 2 (0.8) 2 (0.8) 0 0
Severe skin reaction 2 (0.8) 1 (0.4) 3 (1.2) 3 (1.2)
Thyroiditis 2 (0.8) 0 0 0
Adrenal insufficiency 1 (0.4) 1 (0.4) 0 0
Myositis 0 0 1 (0.4) 1 (0.4)
*  The as-treated population included all the patients who received at least one dose of study treatment.
†  Events were attributed to treatment by the investigator and are listed as indicated by the investigator on the case-report form. Although de-
creased neutrophil count and neutropenia may reflect the same condition, they were listed by the investigators as two distinct events; this 
was also the case for peripheral sensory neuropathy and peripheral neuropathy and for fatigue and asthenia.
‡  Events are listed in descending order of frequency in the pembrolizumab group.
§  The events of interest are those with an immune-related cause and are considered regardless of attribution to study treatment by the inves-
tigator. They are listed in descending order of frequency in the pembrolizumab group. In addition to the specific preferred terms listed, re-
lated terms were also included.
Table 2. Adverse Events in the As-Treated Population.*
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patients), septic shock (in one), and unspecified 
cause (in one).
The most common treatment-related adverse 
events of any grade were pruritus (19.5% of the 
patients), fatigue (13.9%), and nausea (10.9%) in 
the pembrolizumab group and alopecia (37.6%), 
fatigue (27.8%), and anemia (24.7%) in the chemo-
therapy group (Table 2). There were no treatment-
related events of grade 3, 4, or 5 severity that 
occurred with an incidence of 5% or more in the 
pembrolizumab group. In the chemotherapy 
group, treatment-related events of grade 3, 4, or 5 
severity with an incidence of 5% or more were 
neutropenia (13.3%), decreased neutrophil count 
(12.2%), anemia (7.8%), febrile neutropenia (7.1%), 
and decreased white-cell count (5.1%). A sum-
mary of all the adverse events with an incidence 
of 5% or more, regardless of whether they were 
attributed to treatment by the investigator, is pro-
vided in Table S5 in the Supplementary Appendix.
The adverse events of interest with regard to 
pembrolizumab, regardless of whether they were 
attributed to study treatment by the investigator, 
are shown in Table 2. The only events of grade 3, 
4, or 5 severity that were observed in two or more 
patients who were treated with pembrolizumab 
were pneumonitis (2.3% of the patients), colitis 
(1.1%), and nephritis (0.8%); there was only one 
grade 5 event (0.4%), which was pneumonitis.
Discussion
In this randomized, phase 3 study involving pa-
tients with advanced urothelial cancer that pro-
gressed during or after platinum-based chemo-
therapy, pembrolizumab resulted in significantly 
longer overall survival — by approximately 
3 months — than the investigator’s choice of 
paclitaxel, docetaxel, or vinflunine (10.3 months 
vs. 7.4 months). Pembrolizumab had a better 
safety profile than did chemotherapy. The benefit 
of pembrolizumab over chemotherapy was seen 
in the total population, as well as in the copri-
mary population of patients who had a tumor 
PD-L1 combined positive score of 10% or more.
The overall survival benefit with pembrolizu-
mab was observed across almost all the sub-
groups examined and was similar regardless of 
investigator’s choice of chemotherapy. In this 
trial, the benefit of pembrolizumab appeared to 
be independent of PD-L1 expression on tumor 
and infiltrating immune cells. The results of on-
going randomized, controlled trials currently be-
ing conducted in earlier lines of treatment may 
help elucidate the role of PD-L1 expression as a 
biomarker in urothelial carcinoma. A relationship 
between smoking status and the relative benefit 
of pembrolizumab was observed. The relation-
ship between smoking and the relative benefit of 
immunotherapy has also been observed in patients 
with other advanced cancers8,18 and may reflect 
a high mutational load in current and former 
smokers.19 Genomic analysis of this relationship 
is warranted. The median overall survival of 7.4 
months that was observed with chemotherapy is 
consistent with historical data for second-line, 
single-agent treatment.4-7
Pembrolizumab resulted in a significantly 
higher objective response rate than chemother-
apy. Most responses in patients in the pembrolizu-
mab group occurred quickly and were reported 
at the first scheduled imaging assessment. Con-
tinued disease regression over time in some pa-
tients resulted in radiologically confirmed respons-
es that were reported as long as 6.3 months after 
the start of therapy. As compared with responses 
in the chemotherapy group, responses in the pem-
brolizumab group were durable, with a median 
duration of response that was not reached over a 
median follow-up of 14.1 months. On the basis of 
the Kaplan–Meier estimates, 68% of the respons-
es to pembrolizumab were ongoing at 12 months.
Durable responses in patients with advanced 
urothelial cancer have also been observed with 
the anti–PD-L1 antibodies atezolizumab,10 durvalu-
mab,13 and avelumab14 and the anti–PD-1 anti-
body nivolumab.11 Atezolizumab and nivolumab 
are approved only in the United States for the 
treatment of advanced urothelial cancer that 
progressed during or after receipt of previous 
platinum-based chemotherapy. Accelerated approv-
al of these two antibodies was based on objective-
response data from single-group studies.10,11 
Pembrolizumab has now been shown to result in 
a significant survival benefit over standard-of-
care therapy in a large, randomized trial in this 
population.
Overall, there was no significant difference 
between pembrolizumab and chemotherapy 
with regard to progression-free survival. Beyond 
6 months, the progression-free survival curves 
diverged in favor of pembrolizumab. Similar 
findings have been observed with checkpoint 
inhibitors in other tumor types20-24 and suggest 
that in contrast to its use as a surrogate end 
point in historical chemotherapy studies, progres-
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sion-free survival may not be a reliable surrogate 
end point for the clinical benefit of immuno-
therapy. The prolonged duration of response was 
seen only in patients who had a response to 
pembrolizumab, and because less than half the 
patients had a response, the therapy did not exert 
an effect on median progression-free survival. 
However, the duration of response in patients 
who had a response was much longer than the 
duration of response that was seen with chemo-
therapy.
The safety profiles that were observed with 
pembrolizumab and chemotherapy were as ex-
pected, with no new or unexpected toxic effects. 
Immune-mediated adverse events with pembro-
lizumab were relatively infrequent and were 
mostly of grade 1 or 2 severity. Overall, the inci-
dence of treatment-related adverse events was 
substantially lower with pembrolizumab than 
with standard chemotherapy, including fewer 
events of grade 3, 4, or 5 severity and fewer 
events that resulted in the discontinuation of 
treatment. The number of treatment-related deaths 
was the same in the pembrolizumab group and 
the chemotherapy group, which probably re-
f lects the poor prognosis of patients in this 
population. The better safety profile of pembro-
lizumab than of standard chemotherapy is im-
portant, considering that patients with recurrent 
or refractory urothelial carcinoma are generally 
older and have poor performance status and 
multiple coexisting conditions.
The survival benefit that was observed with 
pembrolizumab in this previously treated popula-
tion of patients with a poor prognosis supports 
its study in earlier stages of disease. Currently, 
pembrolizumab and other PD-1 and PD-L1 in-
hibitors are being evaluated as adjuvant therapy 
and as first-line therapy for advanced disease in 
ongoing clinical trials (e.g., ClinicalTrials.gov num-
bers, NCT02450331, NCT02516241, NCT02632409, 
NCT02807636, and NCT02853305).
In conclusion, pembrolizumab resulted in sig-
nificantly longer overall survival — by approxi-
mately 3 months — than the investigator’s choice 
of paclitaxel, docetaxel, or vinflunine and was 
associated with a higher rate of objective re-
sponse and a lower rate of treatment-related 
adverse events than chemotherapy as second-line 
therapy in patients with advanced urothelial carci-
noma that progressed during or after platinum-
based chemotherapy, regardless of tumor PD-L1 
expression status.
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